Schering-Plough (SGP) Announces Hepatitis C Data Presentations
More News related to SGP
- Santarus (SNTS) Earns $20 Million Milestone on FDA Approval for NDA of ZEGERID
- "AIM"ING FOR BETTER ASTHMA CARE
- Merck and Schering-Plough to Complete Merger Today
- Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
- Schering-Plough Announces Sponsorship of Rabies-Control Projects in India
More News related to FDA
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
A total of 20 oral and poster presentations on clinical studies with Schering-Plough's (NYSE: SGP)hepatitis products, including PEGINTRON and REBETOL combination therapy for chronic hepatitis C virus (HCV) infection, as well as boceprevir, the company's investigational oral HCV protease inhibitor currently in Phase II clinical development, will be presented by leading researchers at the 38th annual Digestive Disease Week (DDW) meeting to be held at the Washington Convention Center in Washington, D.C., May 20-23.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
